澳大利亚研究称,亲人去世,β阻滞剂+阿司匹林可防“心碎”

2020-02-13 xujing 中国循环杂志

丧亲之痛,是每个人最伤心的经历。澳大利亚学者在美国心脏杂志发表的一项随机随意研究提示,亲人去世,心痛不已,而短期内应用β受体阻滞剂美托洛尔和阿司匹林可预防心脏病发作或“心碎”风险。研究者发现,亲人去世带来的心脏病发作风险的增加可能持续6个月。在丧亲后的头几天,风险最高。该研究纳入了85名受试者,均在2周内经历了亲人去世。平均年龄66.1岁。42名受试者在6周内每天接受低剂量的美托洛尔和阿司匹林,4

丧亲之痛,是每个人最伤心的经历。

澳大利亚学者在美国心脏杂志发表的一项随机随意研究提示,亲人去世,心痛不已,而短期内应用β受体阻滞剂美托洛尔和阿司匹林可预防心脏病发作或“心碎”风险。

研究者发现,亲人去世带来的心脏病发作风险的增加可能持续6个月。在丧亲后的头几天,风险最高。

该研究纳入了85名受试者,均在2周内经历了亲人去世。平均年龄66.1岁。

42名受试者在6周内每天接受低剂量的美托洛尔和阿司匹林,43名受试者服用安慰剂。监测心率、血压以及凝血指标。

研究者发现,每天服用一次美托洛尔和阿司匹林,有效地降低了血压和心率,对于血凝指标也有积极的影响。

而且,服用这些药物还减轻了焦虑和抑郁症状。

令人惊讶的是,即使停止每天服用美托洛尔和阿司匹林后,焦虑和血压水平仍会降低。

来源:Geoffrey H. Tofler et al. The effect of metoprolol and aspirin on cardiovascular risk in bereavement: A randomized controlled trial, American Heart Journal, American Heart Journal, 2020, 220: 264-272.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2085833, encodeId=c553208583375, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Fri Sep 04 03:09:00 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718237, encodeId=f08e1e18237b5, content=<a href='/topic/show?id=bf431925337' target=_blank style='color:#2F92EE;'>#β阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19253, encryptionId=bf431925337, topicName=β阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eaba32519184, createdName=zhzhxiang, createdTime=Thu Aug 27 21:09:00 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483979, encodeId=ad9514839e949, content=<a href='/topic/show?id=66a666e3784' target=_blank style='color:#2F92EE;'>#澳大利亚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66737, encryptionId=66a666e3784, topicName=澳大利亚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33da7929339, createdName=12498cbcm02(暂无昵称), createdTime=Sat Feb 15 07:09:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625643, encodeId=ab8d162564302, content=<a href='/topic/show?id=1d813e2239c' target=_blank style='color:#2F92EE;'>#去世#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37223, encryptionId=1d813e2239c, topicName=去世)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cf720829073, createdName=psybestwish, createdTime=Sat Feb 15 07:09:00 CST 2020, time=2020-02-15, status=1, ipAttribution=)]
    2020-09-04 zhyy88
  2. [GetPortalCommentsPageByObjectIdResponse(id=2085833, encodeId=c553208583375, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Fri Sep 04 03:09:00 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718237, encodeId=f08e1e18237b5, content=<a href='/topic/show?id=bf431925337' target=_blank style='color:#2F92EE;'>#β阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19253, encryptionId=bf431925337, topicName=β阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eaba32519184, createdName=zhzhxiang, createdTime=Thu Aug 27 21:09:00 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483979, encodeId=ad9514839e949, content=<a href='/topic/show?id=66a666e3784' target=_blank style='color:#2F92EE;'>#澳大利亚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66737, encryptionId=66a666e3784, topicName=澳大利亚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33da7929339, createdName=12498cbcm02(暂无昵称), createdTime=Sat Feb 15 07:09:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625643, encodeId=ab8d162564302, content=<a href='/topic/show?id=1d813e2239c' target=_blank style='color:#2F92EE;'>#去世#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37223, encryptionId=1d813e2239c, topicName=去世)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cf720829073, createdName=psybestwish, createdTime=Sat Feb 15 07:09:00 CST 2020, time=2020-02-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2085833, encodeId=c553208583375, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Fri Sep 04 03:09:00 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718237, encodeId=f08e1e18237b5, content=<a href='/topic/show?id=bf431925337' target=_blank style='color:#2F92EE;'>#β阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19253, encryptionId=bf431925337, topicName=β阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eaba32519184, createdName=zhzhxiang, createdTime=Thu Aug 27 21:09:00 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483979, encodeId=ad9514839e949, content=<a href='/topic/show?id=66a666e3784' target=_blank style='color:#2F92EE;'>#澳大利亚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66737, encryptionId=66a666e3784, topicName=澳大利亚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33da7929339, createdName=12498cbcm02(暂无昵称), createdTime=Sat Feb 15 07:09:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625643, encodeId=ab8d162564302, content=<a href='/topic/show?id=1d813e2239c' target=_blank style='color:#2F92EE;'>#去世#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37223, encryptionId=1d813e2239c, topicName=去世)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cf720829073, createdName=psybestwish, createdTime=Sat Feb 15 07:09:00 CST 2020, time=2020-02-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2085833, encodeId=c553208583375, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Fri Sep 04 03:09:00 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718237, encodeId=f08e1e18237b5, content=<a href='/topic/show?id=bf431925337' target=_blank style='color:#2F92EE;'>#β阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19253, encryptionId=bf431925337, topicName=β阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eaba32519184, createdName=zhzhxiang, createdTime=Thu Aug 27 21:09:00 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483979, encodeId=ad9514839e949, content=<a href='/topic/show?id=66a666e3784' target=_blank style='color:#2F92EE;'>#澳大利亚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66737, encryptionId=66a666e3784, topicName=澳大利亚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33da7929339, createdName=12498cbcm02(暂无昵称), createdTime=Sat Feb 15 07:09:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625643, encodeId=ab8d162564302, content=<a href='/topic/show?id=1d813e2239c' target=_blank style='color:#2F92EE;'>#去世#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37223, encryptionId=1d813e2239c, topicName=去世)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cf720829073, createdName=psybestwish, createdTime=Sat Feb 15 07:09:00 CST 2020, time=2020-02-15, status=1, ipAttribution=)]

相关资讯

JAMA Intern Med:老年AMI患者使用β阻滞剂的利弊分析,全在这里!

尽管β-受体阻滞剂是急性心肌梗死(AMI)后的主要治疗药物,但是这些药物通常没有在AMI后的老年疗养院人群的处方中出现,部分原因是担心潜在的功能损害和受益的不确定性。来自美国的研究人员开展了一项研究,该研究的目的是探讨在接受长期护理的65岁及以上老年人群中,AMI后β受体阻滞剂与功能下降,死亡率和再住院的关系。该疗养院AMI居民队列研究于2007年5月1日至2010年3月31日期间进行,研究人员使

Lancet:代偿性肝硬化伴门脉高压症患者使用β阻滞剂可改善预后

研究认为,代偿性肝硬化伴门脉高压症患者长期应用β阻滞剂可提高生存率

ACC2018:得不偿失!围手术期大剂量β阻滞剂增加死亡风险

在ACC2018年科学会议上公布的POISE研究12个月随访结果表明:对于行非心脏手术却存在心脏风险的患者,与安慰剂相比,围术期使用美托洛尔能预防少心脏事件,但增加了死亡率和卒中发生率。

冠心病应用β阻滞剂严重不规范!报告67家医院1.3万例冠心病患者数据

ESC官网近日报告,在正在举行的第30届长城国际心脏病学会议(GW-ICC)上,阜外医院唐熠达和汪京嘉报告了一项入选我国24城市67家医院1.3万例患者的研究。

Pediatrics:妊娠后期暴露β阻滞剂增加婴儿低血糖和心动过缓风险

β阻滞剂在怀孕期间被广泛应用于治疗高血压疾病。这些药物穿过胎盘,可能导致子宫内新生儿的生理变化。在一项全国性队列研究中,研究人员试图确定在母体内暴露β阻滞剂与新生儿低血糖和心动过缓风险之间的联系。 研究人员链接到2292116名活产婴儿的数据,他们的妈妈在2003年至2007年期间被招募参与此研究。研究人员检查了新生儿低血糖和心动过缓风险与在母体内暴露β受体阻断剂之间的联系。倾向评分匹配